Ownership and insider activity for Nyxoah S.A. (NYXH): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Nyxoah SA, a medical technology company, develops and commercializes solutions to treat obstructive sleep apnea (OSA). The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, minimally invasive, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah SA was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Price
| Price | $1.55 |
| Market Cap | $155M |
| Exchange | NASDAQ |
| Country | BE |
Balance Sheet (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $10.1M | $16.8M | $6.6M | $112.9M | $135.5M | $17.9M | $21.6M | $34.2M | $30.0M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | $77.0M | $36.1M | $51.4M | $18.0M |
| Receivables | $46000 | $732000 | $2.4M | $2.0M | $2.5M | $2.2M | $5.6M | $6.2M | $7.7M |
| Inventory | 0 | 0 | 0 | $67295 | $346000 | $882000 | $3.3M | $4.7M | $4.7M |
| Total Current Assets | $10.7M | $17.5M | $9.0M | $115.1M | $140.1M | $100.3M | $68.4M | $98.1M | $61.2M |
| Property, Plant & Equipment | $369000 | $343000 | $1.6M | $4.9M | $5.2M | $5.6M | $8.0M | $8.2M | $5.3M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | $6.4M | $19.4M | $25.3M | $40.0M | $46.6M | $50.4M | $50.1M |
| Total Assets | $11.1M | $18.0M | $17.1M | $139.6M | $170.8M | $146.1M | $124.2M | $158.4M | $118.4M |
| Accounts Payable | $389000 | $606000 | $1.6M | $1.5M | $2.4M | $1.9M | $4.1M | $3.7M | $13.7M |
| Short-term Debt | $395000 | $289000 | $805954 | $1.3M | $554000 | $389000 | $364000 | $248000 | $23.8M |
| Total Current Liabilities | $1.7M | $2.0M | $4.9M | $7.8M | $11.6M | $14.9M | $14.4M | $21.5M | $48.9M |
| Long-term Debt | $4.9M | $5.5M | $8.0M | $9.3M | $7.8M | $8.2M | $8.4M | $18.7M | $17.7M |
| Total Liabilities | $6.6M | $7.5M | $14.4M | $20.7M | $22.2M | $25.7M | $26.1M | $45.2M | $69.3M |
| Retained Earnings | -$30.7M | -$39.8M | -$54.3M | -$73.8M | -$87.2M | -$118.2M | -$160.8M | -$217.7M | -$305.9M |
| Total Equity | $4.5M | $10.5M | $2.7M | $118.9M | $148.6M | $120.3M | $98.0M | $113.3M | $49.1M |
| Total Debt | $5.3M | $5.8M | $9.7M | $14.1M | $11.7M | $11.9M | $12.7M | $22.7M | $42.1M |
| Net Debt | -$4.8M | -$11.0M | $3.1M | -$98.8M | -$123.8M | -$83.0M | -$45.0M | -$62.9M | -$5.9M |
| Working Capital | $8.9M | $15.5M | $4.0M | $107.3M | $128.5M | $85.3M | $53.9M | $76.6M | $12.3M |
Financial Health
| Debt / Equity | 0.63 |
| Current Ratio | 2.38 |
Profitability
| Return on Equity | -179.71% |
| Return on Invested Capital | -59.89% |
| Return on Assets | -58.46% |
| Gross Margin | 51.31% |
| Operating Margin | -383.05% |
| Net Margin | -434.72% |
Related companies: CATX · GNFT · IVVD · KRMD · OABI · OSUR · PRE
Explore sector: Healthcare · Medical - Specialties
More sections of NYXH: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks